This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 monotherapy atopic dermatitis trials

Ticker(s): LLY

Who's the expert?

Institution: Alliance Dermatology

Dr. Nguyen is from Baton Rouge, Louisiana. He completed his undergraduate studies at Louisiana State University where he received a Bachelor of Science degree with honors.

After college, he attended medical school at LSU School of Medicine in New Orleans. Prior to starting his dermatology residency, he successfully completed his internship at Charity Hospital. Dr. Nguyen completed his training with the LSU Department of Dermatology in New Orleans. He served as chief resident during his final year of residency

Dr. Nguyen received his board certification by the American Board of Dermatology in 2005.

He is a Diplomate of the American Board of Dermatology and he is a Fellow of the American Academy of Dermatology.

Dr. Nguyen was in private practice in Arlington, Texas for 5 years before starting Alliance Dermatology.

Interview Goal
This call will focus on Lilly's recent announcement of results from the Adjoin trial provided durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing - nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.